Document:

Exhibit
10.38

 

LICENSE AGREEMENT AMENDMENT

 

Inasmuch as NewLink Genetics Corporation of Ames, Iowa,
and the Medical College of Georgia Research Institute of Augusta Georgia, have
a valid and existing License Agreement related to the use of [*] dated September 13, 2005;

 

and

 

Inasmuch as the parties agree that the License Agreement
contains a provision (Section 4.1) for the acquisition of new, related
Improvement Technologies by NewLink arising at MCGRI after the Agreement was
signed

and

 

Inasmuch as the NewLink has reviewed a new Improvement
Technology [*], and wishes to exercise its
option to incorporate this technology into the existing License Agreement
technology portfolio under its standard royalty terms and use conditions,

 

It is Agreed:

 

That
the parties amend the License Agreement relative to its Exhibit A , such
that MCG case [*] is to be included in the
technology portfolio for development and commercialization by NewLink,
effective the date that the License Fee of [*] is received
at MCGRI.

 

This
present amendment shall hereby be considered part of the original License
Agreement and is hereto agreed by representatives of both parties signing
below.

 

 

	
  MEDICAL
  COLLEGE OF GEORGIA RESEARCH INSTITUTE

  	
   

  	
   

  	
  NEWLINK
  GENETICS

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  By

  	
  /s/Betty
  Aldridge

  	
   

  	
   

  	
  By:

  	
  /s/Nicholas
  N. Vahanian

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Betty
  Aldridge

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  Name:

  	
  Nicholas
  N. Vahanian

  
	
   

  	
  Title:

  	
  Executive
  Director

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  Title:

  	
  Chief
  Medical and Operations Officer

  
	
   

  	
  Date:

  	
  4/27/06

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
  Date:
  4/21/06Exhibit 10.39

 

LICENSE AGREEMENT AMENDMENT

 

Inasmuch as NewLink Genetics Corporation of Ames, Iowa,
and the Medical College of Georgia Research Institute of Augusta Georgia, have
a valid and existing License Agreement related to the use of [*] dated September 13, 2005;

 

and

 

Inasmuch as the parties agree that the License Agreement
contains a provision (Section 4.1) for the acquisition of new, related
Improvement Technologies by NewLink arising at MCGRI after the Agreement was
signed

 

and

 

Inasmuch as NewLink has reviewed a new Improvement
Technology [*], and wishes to exercise its
option to incorporate those technologies into the existing License Agreement
technology portfolio under its standard royalty terms and use conditions,

 

It is Agreed:

 

That
the parties amend the License Agreement relative to its Exhibit A , such
that MCG case [*] is to be included in the
technology portfolio for development and commercialization by NewLink,
effective the date that the License Fee of [*] is received
at MCGRI.

 

This
present amendment shall hereby be considered part of the original License
Agreement and is hereto agreed by representatives of both parties signing
below.

 

 

	
  MEDICAL
  COLLEGE OF GEORGIA RESEARCH INSTITUTE

  	
   

  	
   

  	
  NEWLINK
  GENETICS

  
	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  By

  	
  /s/Betty
  Aldridge

  	
   

  	
   

  	
  By:

  	
  /s/Nicholas
  N. Vahanian

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Betty
  Aldridge

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  Name:

  	
  Nicholas
  N. Vahanian

  
	
   

  	
  Title:

  	
  Executive
  Director

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  Title:

  	
  Chief
  Medical and Operations Officer

  
	
   

  	
  Date:

  	
  4/27/06

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
  Date:
  4/21/06Exhibit
10.40

 

LICENSE AGREEMENT AMENDMENT

 

Inasmuch as NewLink Genetics Corporation of Ames, Iowa,
and the Medical College of Georgia Research Institute of Augusta Georgia, have
a valid and existing License Agreement related to the use of  [*] dated September 13,
2005;

 

and

 

Inasmuch as the parties agree that the License Agreement
contains a provision (Section 4.1) for the acquisition of new, related
Improvement Technologies by NewLink arising at MCGRI after the Agreement was
signed

 

and

 

Inasmuch as the NewLink has reviewed a new Improvement
Technology [*], and wishes to exercise its option
to incorporate this technology into the existing License Agreement technology
portfolio under its standard royalty terms and use conditions,

 

It is Agreed:

 

That
the parties amend the License Agreement relative to its Exhibit A , such
that MCG case [*] is to be included in the
technology portfolio for development and commercialization by NewLink,
effective the date that the License Fee of [*] is received
at MCGRI.  All Payments due to the [*] will be coordinated by MCGRI according to the terms
stated in [*].

 

This
present amendment shall hereby be considered part of the original License
Agreement and is hereto agreed by representatives of both parties signing
below.

 

 

	
  MEDICAL
  COLLEGE OF GEORGIA RESEARCH INSTITUTE

  	
   

  	
   

  	
   

  	
  NEWLINK
  GENETICS

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  By

  	
  /s/Betty
  Aldridge

  	
   

  	
   

  	
  By:

  	
  /s/Nicholas
  N. Vahanian

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Betty
  Aldridge

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  Name:

  	
  Nicholas
  N. Vahanian

  
	
   

  	
  Title:

  	
  Executive
  Director

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
  Title:

  	
  Chief
  Medical and Operations Officer

  
	
   

  	
  Date:

  	
  2/13/07

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
   

  	
   

  	
  Date:
  2/6/07Exhibit
10.41

 

Patent
Licence Agreement

 

Date:  1 March 2006

 

Parties

 

1.             Bresagen
Xenograft Marketing Ltd ACN 065 430 328 of 41 Victoria Parade
Fitzroy Victoria, Australia 3065 (Licensor)

 

2.             NewLink
Genetics Corporation of 2901 S Loop Drive, Suite 3900, AMES, Iowa
USA 500100-8646 (Licensee)

 

Background

 

A.            The Licensor
holds the legal and beneficial title in the Intellectual Property Rights
subsisting in the Invention

 

B.            The Licensee
seeks a licence to [*] the
Invention in the Fields.

 

C.            The Licensor has
agreed to grant the licence sought on the terms set out in this Agreement.

 

Agreed Terms

 

1.             Term

 

1.1          Initial
term

 

This
Agreement commences on the Effective Date, and unless terminated earlier in
accordance with this Agreement, will continue to operate for an initial period
of 8 years.  (Initial Term).

 

1.2          Extension
of Initial Term

 

(a)           The parties may extend the
Initial Term for a further 5 years provided that the agreement to extend
(including as to amount of annual fees payable) has been reached, reduced to
writing and executed by the parties at least one month prior to the expiration
of the current Initial Term.

 

(b)           Subject to clause 1.2(a),
the parties acknowledge and agree that any extension of the Term will not vary,
reduce or effect the operation of the remaining provisions of this Agreement,
unless otherwise agreed by the parties in writing.

 

2.             Licence

 

2.1          Grant
of Licence

 

(a)           The Licensor grants the
Licensee a non-exclusive licence to [*] using the
Invention in the Fields for the Term and in the Territory with effect from the
Effective Date.

 

(b)           For the avoidance of doubt,
under the licence granted in clause 2.1(a) the Licensee may:

 

(i)            [*];

 

(ii)           [*];

 

but
the Licensee may not without prior approval from the Licensor (which approval [*]):

 

(iii)          [*]; or

 

(iv)          [*].

 

2.2          Delivery
and assistance in the generation of samples

 

The
Licensor will deliver or arrange for the delivery of:

 

(a)           [*]; and

 

(b)           [*],

 

to
the Licensee at the Licensee’s costs within a reasonable time, not to exceed [*] after the Effective Date.

 

2.3          Conditions
of use

 

(a)           In the Licensee’s use of the
Invention, it must do so:

 

(i)            efficiently, with due care
and skill and to the best of its knowledge and expertise;

 

(ii)           in accordance with the
Licensor’s policy and procedures that are provided in writing to Licensee and
all reasonable written directions which the Licensor may give from time to
time; and

 

(iii)          in compliance with all
applicable laws and regulations.

 

1

 

(b)           The Licensee will not
publish any material or make any media release in relation to this Agreement or
the parties’ relationship under this Agreement without the prior written
consent of the Licensor.

 

(c)           The Licensee must not use
the Licensors name, or any trade mark or logo of the Licensor or a Related Body
Corporate of the Licensor without the Licensors prior written consent.  The Licensor must not use the Licensee’s
name, or any trade mark or logo of the Licensee without the Licensee’s prior
written consent.

 

(d)           Any authorised publication
or media release made by the Licensee in relation to this Agreement must
acknowledge the Licensors rights in the Invention and Patent Rights and the
Licensors contributions to the development of the Results.

 

2.4          No right
to sublicense

 

The
Licensee may not sublicense or transfer any part of its rights or obligations
conferred or imposed upon it under this Agreement without the Licensors prior
written consent (which may be withheld at the Licensors sole and absolute discretion).

 

3.             Ownership
of the Results

 

The
parties acknowledge and agree that all rights (including Intellectual Property
Rights) in the Results vest in the Licensee from the date of their creation.

 

4.             Payment

 

4.1          Initial
and ongoing payments

 

The
Licensee must pay to the Licensor:

 

(a)           a non-refundable initial
licence fee of US$[*] on the
Commencement Date; and

 

(b)           US$[*]
on each anniversary of the Effective Date for the Term.

 

4.2          Late
payment

 

Without
prejudice to the Licensor’s other rights, if the Licensee fails to make any
payment by the due date the Licensor may:

 

(a)           suspend performance of its
obligations under this Agreement until such time as all payments due by the
Licensee are paid in full; and

 

(b)           charge daily interest on the
amount outstanding:

 

(i)            calculated from the due date
of payment to the date of actual payment; and

 

(ii)           at the interest rate which
was quoted on the due date of payment (and if no rate was quoted on that day,
the day on which it is next quoted) for overdrafts over $100,000 by the
Australian licensed bank the Licensor mainly uses.

 

4.3          Other
rights and obligations not affected

 

The
exercise by the Licensor of any of its rights under clause 4.2 does not affect:

 

(a)           the Licensee’s obligation to
pay any money due and payable; or

 

(b)           any other rights or remedies
the Licensor may have in relation to any failure by the Licensee to pay an
amount due,

 

under
this Agreement or any other agreement between the Licensor and the Licensee.

 

4.4          Withholding
Taxes

 

The
Licensee is responsible for paying all taxes it becomes liable for in
connection with this Agreement, including any Withholding Taxes.  Where the Licensee is unable to make any
payment to the Licensor without a deduction or withholding, at the time of
payment the Licensee must pay the Licensor the deducted or withheld amount
so  that the net amount received by the
Licensor equals the full amount payable if no such deduction or withholding had
been made.  In this clause Withholding Tax means any withholding tax payable in respect
of any payment paid or deemed to be paid under or in connection with this
Agreement.

 

5.             Records,
reporting and inspection

 

5.1          Licensee
to retain records

 

The
Licensee must maintain separate and accurate records of:

 

(a)           its testing of the Invention;

 

(b)           the Results and its
development of the Results related to the use of Invention; and

 

(c)           payments that it makes to
the Licensor under this Agreement.

 

2

 

5.2          Licensors
right to inspect the records and premises

 

(a)           The Licensor may upon
reasonable written notice enter the premises of the Licensee and inspect those
premises and any materials or information located there that are solely related
to Licensee’s use of the Invention, to verify that the Licensee is complying
with this Agreement.  Such inspection may
be conducted no more than once every twelve (12) months, during Licensee’s
regular business hours and in such a manner as not to unreasonably interfere
with Licensee’s normal business activities.  
Any materials and information inspected by Licensor and the results of
any such inspection shall be the Confidential Information of Licensee and
subject to clause 8.

 

(b)           The Licensee must make the
records under clause 5.1 available for inspection by the Licensor on reasonable
written request from the Licensor.  Such
request may be made no more than once every twelve (12) months.  All such records shall be treated as the
Confidential Information of Licensee and subject to clause 8.

 

6.             Intellectual
Property Rights protection

 

6.1          Licensor
obligations

 

The
Licensor may at its absolute and sole discretion and expense file, prosecute,
register and maintain any Intellectual Property Rights in relation to the
Invention.

 

6.2          Licensee
obligations

 

(a)           The Licensee must comply, at
the Licensor’s sole expense, with all reasonable directions of the Licensor in
relation to the Licensor’s obligations specified in clause 6.1.

 

(b)           The Licensee must not at any
time, register, attempt to register or use any of the Patent Rights in its own
name or other name as proprietor or otherwise.

 

(c)           The revocation or expiry of
the Patent Rights will not affect the validity of this Agreement or the
obligation of the Licensee to make payments under this Agreement.

 

(d)           The Licensee must not
challenge the Licensor’s title or right to the Patent Rights.

 

7.             Infringement
and legal action

 

7.1          Licensee
to notify infringing action

 

The
Licensee must promptly notify the Licensor of any infringement or suspected
infringement of the Patent Rights.

 

7.2          Action
taken by Licensor

 

If
the Patent Rights are infringed, the Licensor may take reasonable steps
including commencing proceedings to prevent further infringement and to protect
the Licensor’s interests in the Invention. 
Unless the Licensor and the Licensee agree in writing, the Licensee will
have no right to commence proceedings.

 

7.3          Claims
against Licensee

 

If
a third party commences an action against the Licensee relating to the
Invention, the Licensee may defend or settle the action or claim only with
prior written approval from the Licensor, such approval not to be unreasonably
withheld or delayed.

 

7.4          Co-operation
by Licensee

 

If
the Licensor defends or starts 
proceedings,  the Licensee must
fully co-operate in the proceedings, at 
Licensor’s sole expense, including providing documents and witnesses to
give evidence in those proceedings.

 

8.             Confidentiality

 

8.1          Obligations
of confidentiality

 

Each
party (Receiving Party) receiving, possessing
or otherwise acquiring Confidential Information of any other party (Disclosing Party) acknowledges that the Disclosing Party’s
Confidential Information is the property of and confidential to or a trade
secret of the Disclosing Party.  Subject
to clause 8.2, the Receiving Party must:

 

(a)           keep the Disclosing Party’s
Confidential Information confidential and not directly or indirectly disclose,
divulge or communicate that Confidential Information to, or otherwise place
that Confidential Information at the disposal of, any other person without the
prior written approval of the Disclosing Party;

 

(b)           limit access to the
Confidential Information of the Disclosing Party to only those of the Receiving
Party’s employees or authorized representatives having a need to know and who
have signed confidentiality agreements containing, or are otherwise bound by,
confidentiality obligations at least as restrictive as those contained herein;

 

(c)           take all reasonable steps to
secure and keep secure all Disclosing Party’s Confidential Information coming
into its possession or control; and

 

3

 

(d)           not memorise, use, modify,
reverse engineer or make copies, notes or records of the Disclosing Party’s
Confidential Information for any purpose other than in connection with the performance
by the Receiving Party of its obligations under this Agreement.

 

8.2          Exceptions

 

The
obligations of confidentiality under clause 8.1 do not apply to any information
that:

 

(a)           is at the time of disclosure
or subsequently becomes generally available to the public (other than by reason
of a breach of this Agreement);

 

(b)           was in the Receiving Party’s
possession free of any obligation of confidence at the time it was disclosed to
the Receiving Party, as can be demonstrated by written records;

 

(c)           was rightfully communicated
to the Receiving Party free of any obligation of confidence subsequent to the
time it was disclosed to the Receiving Party; or

 

(d)           is required to be disclosed
by any applicable law, provided that the Receiving Party provides the Disclosing
Party with reasonable prior written notice of such disclosure and makes a
reasonable effort to obtain, or to assist the Disclosing Party in obtaining, a
protective order preventing or limiting the disclosure and/or requiring that
the Confidential Information so disclosed be used only for the purposes for
which the law or regulation required, or for which the order was issued.

 

9.             Warranties
and exclusions

 

9.1          Licensor
warranties

 

The
Licensor represents and warrants to the Licensee that on the date of this
Agreement and to the Licensors actual knowledge, the following warranties are
true and correct and not misleading:

 

(a)           it has full right, power,
and authority to grant the licence in clause 2.1.

 

9.2          Licensee’s
warranties

 

The
Licensee represents and warrants to the Licensor that on the date of this
Agreement the following warranties are true and correct and not misleading:

 

(a)           it has made its own
commercial assessment of the Invention and the Patent Rights, the commercial
value of the licence granted under this Agreement; and

 

(b)           it has the necessary
technical expertise to use the Invention for the purposes permitted by the
licence granted under clause 2.1.

 

9.3          Reliance
on representations and warranties

 

The
Licensee acknowledges that the Licensor has executed this Agreement and agreed
to take part in the transactions contemplated by this Agreement in reliance on
the representations and warranties that are made in this clause 9.

 

9.4          Exclusion
of implied warranties

 

The
Licensee acknowledges that it is familiar with the Invention.  Accordingly, except where prohibited by the Trade Practices Act 1974 (Cth) or other legislation, all
warranties, conditions, representations and statements (whether express or
implied and statutory or otherwise) regarding the condition of the Invention
are excluded including those of merchantability and fitness for a particular
purpose.

 

10.          Limitation
of liability

 

10.1        Limitations
on liability

 

(a)           Subject to this clause 10,
except for breathes of the obligations set forth in clause 8 (Confidentiality),
the Licensor is not liable to the Licensee or to any other person for:

 

(i)            any losses or damages of any
kind caused by or resulting from any wrongful, wilful or negligent act or
omission of the Licensor or a Related Body Corporate of the Licensor and any of
their officers, employees, agents or contractors; or

 

(ii)           any indirect, incidental,
special or consequential damages, including loss of profits or anticipated
profits, even if notified of the possibility of that potential loss or damage.

 

(b)           Subject to this clause 10,
except for breaches of the obligations set forth in clause 6 (Confidentiality)
and clause 2 (Licence) and amounts for which Licensee is obligated to indemnify
pursuant to clause 11 (Indemnity), the Licensee is not liable to the Licensor
or to any other person for any indirect, incidental, special or consequential
damages, including loss of profits or anticipated profits, even if notified of
the possibility of that potential loss or damage.

 

4

 

10.2        Maximum
liability

 

Subject
to the liability limitation exceptions in clause 10.1(a) and clause
10.1(b), the maximum aggregate liability 
of either party for all proven losses, damages and claims arising out of
this Agreement, including liability for breach, in negligence or in tort or for
any other common law or statutory action, is limited to the total payment   paid by the Licensee to the Licensor under
this Agreement in the first year of the Term.

 

10.3        Exclusion
of implied warranties

 

Any
representation, warranty, condition or undertaking that would be implied in
this Agreement by legislation, common law, equity, trade, custom or usage is
excluded to the maximum extent permitted by law.

 

10.4        Non-excludable
rights implied by statute

 

Nothing
in this Agreement excludes, restricts or modifies any condition, warranty,
right or remedy conferred on   the
Licensor by the Trade Practices Act 1974 (Cth) or
any other applicable Law that cannot be excluded,   restricted or modified by agreement

 

10.5        Liability
for breach of non-excludable rights

 

To
the fullest extent permitted by law, the liability of the Licensor for a breach
of a non-excludable condition or warranty referred to in clause 10.4 is
limited, at the Licensor’s option, to:

 

(a)           in the case of goods, any
one or more of the following:

 

(i)            the replacement of the goods
or the supply of equivalent goods;

 

(ii)           the repair of the goods;

 

(iii)          the payment of the cost of
replacing the goods or of acquiring equivalent goods; or

 

(iv)          the payment of the cost of
having the goods repaired; or

 

(b)           in the case of services:

 

(i)            the supplying of the
services again; or

 

(ii)           the payment of the cost of
having the services supplied again.

 

10.6        Survival
of clause

 

Despite
any other provision of this Agreement, this clause 10 survives the expiry or
termination of this    Agreement.

 

11.          Indemnity

 

The
Licensee must keep the Licensor indemnified against all claims and proceedings
made or brought against   the Licensor by
a third party and for all loss, damage and expense (including, without
limitation, reasonable legal costs) the Licensor suffers or incurs (directly or
indirectly) arising from:

 

(a)           any breach or
non-performance of this Agreement by the Licensee;

 

(b)           any wrongful, wilful or
negligent act or omission of the Licensee or any of its employees, agents or
contractors;

 

(c)           breach of any third party
rights, including Intellectual Property Rights; or

 

(d)           the use of the Invention,
Patent Rights and Results for any purpose.

 

Licensor
will promptly notify Licensee of any such claim.

 

12.          Insurance

 

12.1        Obligation
to insure

 

The
Licensee must effect and maintain throughout the term of this Agreement, at its
own expense:

 

(a)           all insurances that the
Licensee must effect under any legislation or required by the Licensor; and

 

(b)           any other insurances that a
reasonable and prudent person engaged in the relevant industry would effect and
maintain.

 

12.2        Produce
policies

 

The
Licensee must produce to the Licensor on request, copies of all current
certificates of insurance confirming that each of the required policies is
current.

 

13.          Default
and termination

 

13.1        Mutual
termination

 

The
parties may terminate this Agreement anytime by agreement in writing, each
party not to unreasonably withhold its consent for termination of this
Agreement if requested by the other party.

 

5

 

13.2        Default
notice

 

If
an Event of Default, other than when the Licensee is insolvent or becomes
insolvent, occurs in relation to the Licensee, the Licensor may give a notice (Default Notice) to the Licensee specifying the Event of
Default and requiring the Licensee to remedy the default within 60 Business
Days after the Default Notice is given to the Licensee.

 

13.3        Termination
notice

 

If
the Licensee:

 

(a)           receives a Default Notice
and does not comply with the notice within the relevant period referred to in
clause 13.2; or

 

(b)           receives a Default Notice on
3 occasions in any period of 12 months; or

 

(c)           is insolvent or become
insolvent,

 

then
the Licensor, without limiting its other rights and remedies, may terminate
this Agreement by giving to the Licensee notice with immediate effect.

 

14.          Termination
consequences

 

14.1        Termination
of licence and handover of materials

 

On
termination of this Agreement whether by expiry of the Term or otherwise:

 

(a)           all rights granted to the
Licensee will terminate and all rights in and to the Invention and Patent
Rights will revert to the Licensor without further action or notification by
the Licensor to the Licensee or any other person;

 

(b)           the Licensee must hand over
to the Licensor, or if directed by the Licensor destroy all samples, documents,
data and computer programs concerning the Invention which are in its possession
or control or made available to the Licensee by the Licensor under this
Agreement;

 

(c)           the Receiving Party will
return to the Disclosing Party or destroy all copies and embodiments of the
Disclosing Party’s Confidential Information within 10 days; and

 

(d)           any sums payable to the
Licensor immediately become due and payable.

 

14.2        No
prejudice to other rights

 

A
party’s exercise of any right under this clause 14 does not prejudice any right
to damages or other remedy such party may have against the other party for
breach of this Agreement.

 

14.3        Continuation

 

Clauses
8, 9, 10, 11, 13, 14 and 15 survive termination of this Agreement

 

15.          General

 

(a)           A party will not be liable
for any failure to carry out its obligations under this Agreement where such
failure is due to any cause beyond the reasonable control of that party.

 

(b)           This Agreement contains the
entire understanding between the parties concerning the subject matter of the
Agreement and supersedes all prior communications between the parties.

 

(c)           A failure, delay, relaxation
or indulgence by a party in exercising any power or right conferred on the
party by this Agreement does not operate as a waiver of the power or
right.  A single or partial exercise of
the power or right does not preclude a further exercise of it or the exercise
of any other power or right under this Agreement.  A waiver of a breach does not operate as a
waiver of any other breach.

 

(d)           Any illegal or invalid
provision of this Agreement will be severable and all other provisions will
remain in full force and effect.

 

(e)           The Licensee cannot assign
or otherwise transfer the benefit of this Agreement without the prior written
consent of the Licensor.  Notwithstanding
the foregoing, the Licensee may assign this Agreement in whole, with reasonable
prior written notice to the Licensor, to a successor in interest to all, or
substantially all, of the assets of the Licensee whether by merger,
acquisition, purchase, or otherwise.

 

(f)            This Agreement cannot be
amended or varied except in writing signed by the parties.

 

(g)           This Agreement is governed
by and must be construed in accordance with the laws in force in the State of
Victoria, Australia.  The parties submit
to the exclusive jurisdiction of the courts of that State and the Commonwealth
of Australia in respect of all matters arising out of or relating to this
Agreement, its performance or subject matter.

 

(h)           Any notice or other
communication to or by a party to this Agreement must be in writing whether
given by personal service, post, facsimile or email, to the other party’s
contact address as specified above or as otherwise notified by other party from
time to time.

 

6

 

(i)            If this Agreement consists
of a number of signed counterparts, each is an original and all of the
counterparts together constitute the same document.

 

(j)            Unless this Agreement
expressly provides otherwise, nothing in this Agreement may be construed as
creating a relationship of partnership, or principal and agent or of trustee
and beneficiary.

 

7

 

Schedule
— Dictionary

 

In
this Agreement:

 

Agreement means this
agreement including the recitals, any schedules and any annexures;

 

Business
Day means a day that is not a Saturday, Sunday, public holiday or bank
holiday in the State of Victoria;

 

Change
of Control means, in relation to a body corporate, the
occurrence of an event or circumstance where a person who is not presently able
to do any of the following things becomes 
able to do one of the following things (whether directly or indirectly
or through one or more intervening persons, companies or trusts):

 

(a)   control the composition of more than one half of the
body’s board of directors;

 

(b)   be in a position to cast, or control the casting of,
more than one half of the maximum number of votes that might be cast at a
general meeting of the members of the body; or

 

(c)   hold or have a beneficial interest in more than one
half of the issued share capital of the body;

 

Commencement
Date means the date of execution of this Agreement;

 

Confidential
Information means all information belonging or relating to a
party to this Agreement, whether oral, graphic, electronic, written or in any
other form, that is not generally available to the public at the time of
disclosure other than by reason of a breach of this Agreement or that is in
fact, or should reasonably be regarded as, confidential to the party to whom it
belongs or relates:

 

(a)   the terms of this Agreement and its subject matter,
including Information submitted or disclosed by a party during negotiations,
discussions and meetings relating to this Agreement;

 

(b)   Information that at the time of disclosure by a
Disclosing Party is identified to the Receiving Party as being confidential;
and

 

(c)   all other Information belonging or relating to a
Disclosing Party, or any Related Body Corporate of that Disclosing Party, that
is not generally available to the public at the 
time of disclosure other than by reason of a breach of this Agreement or
which the Receiving Party knows, or ought reasonably to be expected to know, is
confidential to that Disclosing Party or any Related Body Corporate of that
Disclosing Party;

 

Controller means, in relation to a person:

 

(a)   a receiver, receiver and manager, administrator or
liquidator (whether provisional or otherwise) of that person or that person’s
property; or

 

(b)   anyone else who (whether or not as agent for the
person) is in possession, or has control, of that person’s property to enforce
an Encumbrance;

 

Corporations
Act means the Corporations Act 2001
(Cth); Effective Date means 1 March 2006;

 

Effective
Date means 1 March 2006;

 

Encumbrance means:

 

(a)   an interest or power reserved in or over an interest
in an asset, including any retention of title;

 

(b)   an interest or power created or arising in or over
an interest in an asset under a bill of sale, mortgage, charge, lien, pledge,
trust or other similar instrument, device or power; or

 

(c)   any other adverse right, title or interest of any
nature, by way of security for the payment of a debt or the performance of any
other obligation,

 

and
includes any agreement or arrangement (whether legally binding or not) to grant
or create any of the above;

 

Event
of Default means, in relation to the Licensee, the occurrence
of any one or more of the following events or circumstances:

 

(a)   the Licensee fails to comply with any of its
obligations under this Agreement;

 

(b)   the Licensee is insolvent or becomes insolvent;

 

(c)   a Change of Control occurs in relation to the
Licensee, other than with the consent of the Licensor;

 

(d)   a notice of deregistration of the Licensee is given;

 

(e)   the Licensee fails to pay by the due date any amount
due and payable by it under this Agreement;

 

(f)    any representation, warranty or statement made or
repeated by the Licensee in or in connection with this Agreement is untrue or
misleading in any respect (including by omission) when so made or repeated;

 

(g)   the Licensee becomes unable to perform all of its
obligations and take all actions contemplated under this Agreement;

 

(h)   a material provision of this Agreement that purports
to impose an obligation on the party is or becomes Void, voidable, illegal or
unenforceable or of limited effect (other than because of equitable principles
or laws affecting creditor’s rights generally); or

 

(i)    the Licensee ceases or threatens to cease to carry
on business or a substantial part of it;

 

Fields means:

 

(a)   testing of microbial vaccines; and

 

(b)   testing of cancer vaccines;

 

Intellectual
Property Rights means all present and future intellectual and
industrial properly rights conferred by statute, at common law or in equity and
wherever existing, including:

 

(a)   patents, designs, copyright, rights in circuit
layouts, plant breeder’s rights, trade marks, know how, brand names, domain
names, inventions, product names, trade secrets and any other rights subsisting
in the results of intellectual effort in any field, whether or not registered
or capable of registration;

 

(b)   any application or right to apply for registration
of any of these rights;

 

(c)   any registration of any of those rights or any
registration of any application referred to in paragraph (b); and

 

(d)   all renewals and extensions of these rights;

 

Invention means [*], which is the invention the subject of the Patent
Rights;

 

Patent means a patent
as defined in the Patents Act 1990 (Cth) and any
national or regional patent (whether under the Patent
Cooperation Treaty or not), including a re-issue, renewal or
extension of a patent (whether in whole or in part) and a patent of addition or
a substantially similar form of protection for an invention granted by another
country where the essence is that the holder of the protection gains an
exclusive right to make, use and sell a product or process which is the subject
of that invention;

 

Patent
Rights means the Patent relating to the Invention as described in [*];

 

Related
Body Corporate has the meaning given to that term in the
Corporations Act;

 

Results means the
testing results which are created or developed by or for the Licensee as a
result of the Licensee’s valid use of the Invention under and in accordance
with this Agreement;

 

Schedule means the
schedule to this Agreement;

 

Term means the term
of this Agreement as determined in accordance with clause 1; and

 

Territory means USA.

 

8

 

	
  Executed as an
  agreement

  	
   

  
	
   

  	
   

  
	
  Executed by Bresagen Xenograft Marketing Pty

  	
  )

  
	
  Ltd ACN 065 430
  328 in accordance with its internal

  	
  )

  
	
  rules of
  constitution and governance:

  	
  )

  
	
   

  	
  )

  

 

 

	
   

  	
   

  	
   

  
	
  Signature
  of authroised representative

  	
   

  	
  By
  executing this agreement the signatory is warrants that the signatory is duly
  authorised to execute this agreement on behalf of Bresagen Xenograft
  Marketing Pty Ltd

  

 

 

 

	
   

  	
   

  	
   

  
	
  Name
  and title (please print)

  	
   

  	
   

  

 

 

	
  Executed by NewLink Genetics Corporation in

  	
   

  	
  )

  	
   

  
	
  Accordance
  with its internal rules of constitution and

  	
  )

  	
   

  	
   

  
	
  Governance
  by its authorised officers:

  	
  )

  	
   

  	
   

  
	
   

  	
   

  	
   

  	
  )

  
	
   

  	
   

  	
   

  	
  )

  

 

	
   

  	
   

  	
   

  
	
  Signature
  of authorised officer

  	
   

  	
  Signature
  of authorised officer

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Name
  and title (please print)

  	
   

  	
  Name
  and title (please print)

  

 

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00182-of-00352.parquet"}]]